Comparative study between Spironolactone vs Eplerenone in patients undergoing revascularization with acute myocardial infarction having LV dysfunction

Effect of Spironolactone vs Eplerenone on left ventricular systolic dysfunction in revascularized patients with acute myocardial infarction

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037504

Enrollment

Registered

2021-10-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I219- Acute myocardial infarction, unspecified

Interventions

Intervention1: eplerenone: effect 25mg oral once daily for 3 months Control Intervention1: SPIRONOLACTONE: 50MG oral once daily for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years of age 2. Both M/F 3. Post MI LV Dysfunction (EF revascularization prior to randomization 4. Systolic blood pressure at enrolment would be minimum>=100mmHg irrespective of ongoing beta blocker orACEI

Exclusion criteria

Exclusion criteria: 1. Patients already taking MRAs prior to randomization 2. LV dysfunction of nonischemic/unknown etiology 3. Serum creatinine >2.5 mg/dl 4. History of severe Hyperkalemia (7meq/l)

Design outcomes

Primary

Measure	Time frame
Improvement in LVEF% measured by Simpsonâ??s rule Timepoint: 3 months	—

Secondary

Measure	Time frame
Monitoring change in NYHA functional class. Timepoint: 3 months	—

Countries

India

Contacts

Public ContactTUTAN DAS

AIIMS, BHUBANESWAR

dasdebasish54@gmail.com9862453219

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026